We shall not cease from exploration And the end of all our exploring Will be to arrive where we started And know the place for the first time.—T.S. Eliot
THE WORLD is changing because of the modern application of genetics, and the field of neurology is no exception. From trinucleotide repeats to prions, clinical and physiologic beliefs have been challenged by a continuing expansion of knowledge. The subject of the article by Nagamatsu and colleagues in this issue of the ARCHIVES,1 Charcot-Marie-Tooth disease type 2 (CMT2) has been an object of study in an increasing number of laboratories, although early genetic research involving CMT2 has already provided some interesting insights.